LETTERS TO THE EDITOR

"Alice in Wonderland" syndrome and infectious mononucleosis in children

Visual illusions (metamorphopsia) characterised by distortion of form, size, movement or colour was initially labelled the Alice in Wonderland Syndrome (AWS).¹ It has rarely been reported in children.^{2,3} In 1977 Copperman² reported three patients with metamorphopsia as the initial symptom of infectious mononucleosis (IM). We reported a similar observation.³ We now describe a child with AWS with no obvious history nor relevant clinical signs that suggested active IM but followed a mild clinical, but serologically, proven course of IM.

A six year old girl with an uneventful medical history and no history of migraine, epilepsy or behavioural abnormalities, was referred to us because of metamorphopsia associated with mild headache and anxiety. These episodes recurred several times a day lasting a few minutes each time. Detailed history revealed that two weeks before these symptoms the patient had a "throat infection" with high fever and enlarged cervical lymph nodes. Throat cultures were sterile and the symptoms disappeared gradually without treatment. Physical examination was unremarkable except for the spleen which was palpable 3cm below the costal margin. Neurological examination showed an alert intelligent child who was able to describe her symptoms accurately.

Laboratory findings revealed a white cell blood count of 15000/mm³ with 16% large atypical lymphocytes (Downey's cells). The initial viral capsid antibody titre for Epstein-Barr virus (EBV) was 1:80 and two weeks later 1:20. Epstein-Barr nuclear antibody titres were 1:10 and 1:20 four and six months respectively after the initial episode. Computerised tomography of the brain was normal. An EEG performed a week after the beginning of her complaints was abnormal showing normal background activity of alpha rhythm with a few generalised series of sharp high voltage waves mostly in the parieto-occipital region. Repeat EEG two weeks later was normal. There was complete resolution of the visual symptoms after four weeks. During 12 months of follow up there were no visual complaints nor any other neurological symptoms.

Various neurological and psychiatric symptoms have been described in association with infectious mononucleosis.^{2,4,5} Metamorphopsia, a rarely reported symptom, may appear before the onset^{2,3} or after the resolution of all clinical symptoms, as described in our patient. In all the previously reported patients no neurological deficits were observed. Electroencephalograms were either normal or showed left temporal slow waves. The diagnosis of infectious mononucleosis was clearly established in all patients by the strongly positive haematological and serological findings.^{2,3} The duration of the visual illusions ranged between two weeks and seven months, and all patients recovered completely.

Metamorphopsia has also been related to lesions of the occipital, occipitotemporal or occipitoparietal areas of the brain.⁶ In our patient no structural brain abnormalities were observed, however, the EEG suggested an electrical dysfunction in the parieto-occipital region.

Few patients with AWS secondary to IM have been reported, but this combination may not be that rare. The question of whether these visual illusions of AWS are specific to IM or might be seen in association with other viral diseases, remains unsolved.

ELIEZER LAHAT

GIDEON ESHEL

AHARON ARLAZOROFF*

The Departments of Pediatrics and Neurology,*

Assaf Harofeh Medical Center,

Tel Aviv University,

Sackler School of Medicine,

Zerifin 70300, Israel

Correspondence to: Dr Lahat.

- 1 Todd J. The syndrome of "Alice in Wonderland". *Can Med Assoc J* 1955;73:701-4.
- 2 Copperman SM. "Alice in Wonderland" Syndrome as a presenting symptom of infectious mononucleosis in children: A description of three affected young people. *Clin Pediatr* 1977;16:143-6.
- 3 Eshel GM, Azizi E, Lahat E. Alice in Wonderland syndrome. A manifestation of acute Epstein-Barr virus infection. *Pediatr Infect Dis* 1987;6:68.
- 4 Hendler N, Leahy W. Psychiatric and neurologic sequelae of infectious mononucleosis. *Am J Psychiat* 1978;135:842-4.
- 5 Fisher M, Shenker R, Nussbaum MP. Infectious Mononucleosis. Review of complications in hospitalized series. *NY J Med* 1980;5:929-33.
- 6 Adams RA, Victor M. *Principles of Neurology*. New York: McGraw-Hill, 1981:314.

Infarct in the territory of the medial branch of the PICA

Many cases of small cerebellar infarcts mimicking labyrinthine dysfunction have been reported, but clinico-anatomic correlations were often imprecise.¹⁻⁷ We report a case in which magnetic resonance imaging (MRI) localised the lesion to the territory of the medial branch of the posterior inferior cerebellar artery (PICA).

A 62 year old female was admitted because of a sudden rotatory vertigo accompanied by nausea and vomiting. She was a heavy smoker who had hyperlipidaemia and paroxysmal atrial fibrillation. In April 1987, a right carotid endarterectomy had been performed for a tight stenosis. There was also a tight stenosis of the prevertebral subclavian artery. She was taking aspirin and disopyramide.

On examination, the patient had persistent vertigo, nausea and vomiting. She was unable to walk or stand. There was no spontaneous or initiated nystagmus. Caloric irrigation produced symmetrical responses and there was no directional preponderance. The audiogram was normal. The remainder of the neurological examination was normal and in particular there was no dysmetria or sensory disturbance. CT, with and without contrast, performed on 21 April 1989 was normal. Three days later, the MRI on T1 and T2 weighted sequences revealed a left sided hyperintensity of the nodulus and of the postero-inferior part of the cerebellar hemisphere (fig), consistent with a haemorrhagic infarct in the cerebellar territory of the medial branch of the PICA. The patient's clinical

Figure (a) T1 weighted MRI: hyperintensity of the nodulus. (b) T2 weighted MRI: hyperintensity of the nodulus and of the postero-inferior part of the cerebellar hemisphere.

condition improved spontaneously over 36 hours.

The PICA contributes to the supply of the medulla and cerebellum. In the medulla, it always supplies the dorsal territory, but its contribution to the supply of the lateral part is extremely variable. In the cerebellum, the PICA ends in two branches: a lateral one, which supplies most of the posterior and inferior part of the cerebellar hemisphere and a medial one which supplies the dorsal part of the medulla, the inferior part of the vermis including the nodulus, and the adjacent cerebellar hemisphere.⁸ Infarcts may be limited to the cerebellar territory of this branch as demonstrated by MRI in our case and pathologically in the case of Amarenco *et al.*¹

In both these cases, acute vertigo was the only symptom, neurological examination was normal and there was no noticeable dysmetria. The electronystagmogram performed in our case was normal and caloric irrigation produced symmetrical responses. This syndrome may be explained by the involvement of the nodulus, part of the flocculo-nodular complex, that has primary vestibular connections.

In a comparable case of Duncan *et al.*,² the nodulus was intact but the flocculus, usually supplied by the anterior inferior cerebellar artery (AICA), was involved. Small cerebellar infarcts in which acute vertigo is the only presenting symptom may closely mimic an acute peripheral labyrinthine disorder. Our case supports the view of Guiang *et al.*³ that normal caloric responses suggest a cerebellar lesion.

C MASSON

F CHERON

Clinique Neurologique,

Hôpital Beaujon,

100, Boulevard du Gal Leclerc,

92110 Clichy, France

1 Amarencu P, Hauw JJ, Henin D, et al. Les infarctus du territoire de l'artère cérébelleuse postéro-inférieure. Etude clinico-pathologique de 28 cas. *Rev Neurol* 1989;145:277-86.

2 Duncan GW, Parker SW, Fisher CM. Acute cerebellar infarction in the PICA territory. *Arch Neurol* 1975;32:364-8.

3 Guiang RL, Ellington OB. Acute pure vertiginous disequilibrium in cerebellar infarction. *Eur Neurol* 1977;16:11-15.

4 Huang CY, Yu YL. Small cerebellar strokes may mimic labyrinthine lesions. *J Neurol Neurosurg Psychiatry* 1985;48:263-5.

5 Kömpf D. Der benigne pseudovestibuläre kleinhirninsult. *Nervenarzt* 1986;57:163-6.

6 Rubenstein RL, Norman DM, Schindler RA, Kaseff L. Cerebellar infarction. A presentation of vertigo. *Laryngoscope* 1980;90:505-14.

7 Samson M, Mihout B, Thiebot S, Second G, Weber J, Proust B. Forme bénigne des infarctus cérébelleux. *Rev Neurol* 1981;137:373-82.

8 Amarencu P, Hauw JJ. Anatomie des artères cérébelleuses. *Rev Neurol* 1989;145:267-76.

Efficacy of sublingual apomorphine in Parkinson's disease

Apomorphine administered subcutaneously either by multiple injections or by continuous infusion is used to treat on-off fluctuations in Parkinsonian patients.^{1,2} However, the complexity of the techniques of injection, especially with continuous infusion mini-pumps, and the frequency of local side effects have limited the widespread use of the therapy.²

Apomorphine taken orally reduces the on-off effects in Parkinsonian patients but the high doses (400-1600 mg/day), required to obtain a therapeutic response, leads to dose-dependent uraemia.³

Sublingual apomorphine is prescribed as an emetic in the treatment of alcoholism. The rich vascularisation of the sublingual area makes absorption very rapid. Also, the catabolism of apomorphine may be slowed down by a diminution of the hepatic first-pass metabolism.

We carried out a study to assess the efficacy of sublingual apomorphine in 8 patients with idiopathic Parkinson's disease. Approval for the trial was granted by the ethical committee of the Faculty of Medicine of Clermont-Ferrand. All patients were given 20mg of domperidone three times daily at least 72 hours before the first administration of apomorphine. Levodopa therapy and dopamine agonists were stopped at least three days before the beginning of the trial. The study was in two steps. On day one, apomorphine was injected subcutaneously in one 3mg dose. On day two, patients were given

Figure Time course effect of two different routes of apomorphine in eight Parkinsonian patients. The bars indicate SEM. * $P < 0.05$, † $P < 0.01$, ‡ $P < 0.001$ vs corresponding predrug administration. Statistical analysis was performed with the rank sum two sample test.

18mg (six 3mg tablets) apomorphine sublingually. Assessment of motor function was made by the modified Columbia scale⁴ before administration and every 30 minutes thereafter until therapeutic response ceased. The swiftness of the response, determined by the first signs of improvement in the motor score, and its duration were also measured.

Improvement occurred in all patients whether apomorphine was administered subcutaneously or sublingually (fig). Subcutaneous apomorphine had an effect within a mean time of 14 minutes (extreme values: 10-15 minutes) for a mean duration of 77 minutes (extreme values: 50-110 minutes); these results are in line with those of other reports.^{1,5} The effect of sublingual apomorphine was slower (mean delay of onset: 30 minutes; extreme values: 20-35 minutes) but more sustained (mean duration: 120 minutes; extreme values: 85-200 minutes). The two routes of administration induced a comparable therapeutic response with a maximum mean improvement of 50% in the score on the Columbia scale.

The only drawback to sublingual tablets is their bitter taste. No clinical or biological side effects were observed. Sublingual apomorphine is of interest in the treatment of idiopathic Parkinson's disease because it is simple to administer, harmless when given once and has long-lasting effect. Other studies are required to evaluate more fully this route of administration in Parkinson's disease.

We thank Dr Pollak for his critical review of the manuscript. This work was supported by INSERM grant 89CN17.

F DURIF
D DEFFOND
M TOURNILHAC
Clinique Neurologique, Hôpital Fontmaure, Avenue de Villars, 63400 Chamalières, France.
Correspondence to: Dr Durif

1 Stibe GMH, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in Parkinsonian on-off oscillations. *Lancet* 1988;i:403-6.

2 Pollack P, Champay AS, Gaio GM, Hommel M, Benabib AL, Perret J. Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladie de Parkinson. *Rev Neurol* 1990;146:116-22.

3 Cotzias GC, Papavasiliou PS, Felhing C, Kaufman B, Mena I. Similarities between neurologic effects of the L-Dopa and of apomorphine. *N Eng J Med* 1970;282:31-33.

4 Lhermitte F, Agid Y, Signoret JL. Onset and end of dose levodopa induced dyskinesias. *Arch Neurol* 1978;35:261-3.

5 Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson's disease. *Lancet* 1988;i:943.

CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease

Decreased cortical concentrations of somatostatin-like immunoreactivity (SLI) have been one of the principal biochemical abnormalities found in the brains of patients with Alzheimer's disease.¹ Degeneration of somatostatinergic neurons has also been implicated in the pathophysiology of dementia in Parkinson's disease.² Whereas brain somatostatinergic deficiency seems to be reflected in the cerebrospinal fluid (CSF) of patients with Alzheimer-type dementia,³ studies of somatostatin CSF-concentrations in Parkinson's disease have so far produced conflicting results.^{3,4} This study was performed to re-assess whether CSF-SLI levels are altered in Parkinson's disease and whether there is a correlation between CSF-SLI concentrations and cognitive performance in patients with Parkinson's disease.

Twenty two patients with idiopathic Parkinson's disease undergoing routine inpatient treatment gave informed consent to a diagnostic lumbar puncture. Eleven had a history of progressive deterioration of memory and other intellectual functions (Parkinson-Dementia group), while there was no evidence for dementia in the other 11 patients (non-demented group). Further clinical details are summarised in table 1.

Eleven inpatients [four females, seven males; mean (SD) age 48 (12) years] without clinical evidence of CNS disease for whom CSF samples were available, served as controls, after agreeing to have an identical neuropsychological test battery as the patients (see below). Only patients with normal routine CSF findings were included in this control group.

Neuropsychological tests included: verbal IQ (VIQ) and performance IQ (PIQ) both

Table 1 CSF-SLI in Parkinson's disease (PD)

Group	Patient data (n = 22)				Levodopa		Concomitant treatment drug	Number of patients
	Male: Female	Mean age (range) years	Mean duration of illness (range) years	H + Y stage	Mean dose (range) mg	Mean duration (range) years		
PD with Dementia (N = 11)	6:5	67 (48-76)	9 years (1-21)	3, 4 (2-4)	952 (300-2000)	6, 1 (1-12)	Anticholinergics Bromocriptine Amantadine	4 1 1
PD without Dementia (N = 11)	6:5	61 (45-74)	7, 45 yrs (1-16)	2, 7 (1-4)	760 (400-2100)	5, 6 (1-16)	Anticholinergics Bromocriptine Amantadine	4 1 2

H + Y = Hoehn and Yahr.